NICE recommends CSL Behring’s haemophilia B gene therapy Hemgenix

28 Jun 2024
pmlive.com
Clinical ResultGene Therapy
NICE recommends CSL Behring’s haemophilia B gene therapy Hemgenix
Preview
Source: PMLiVE
The National Institute for Health and Care Excellence (NICE) has recommended CSL Behring’s haemophilia B gene therapy Hemgenix (etranacogene dezaparvovec) for immediate reimbursement by NHS England.
The agency’s positive opinion, which specifically applies to adults with severe or moderately severe haemophilia B without a history of factor IX (FIX) inhibitors, reverses its previous decision to reject the therapy.
Affecting more than 2,000 people in the UK, haemophilia B is a genetic bleeding disorder resulting from missing or insufficient levels of clotting FIX.
Patients with severe cases of the disease currently require lifelong treatment with intravenous FIX, which can still leave them vulnerable to breakthrough bleeds and pain in the days before infusions.
CSL’s Hemgenix addresses the underlying genetic cause of haemophilia B by enabling the body to continuously produce FIX.
NICE’s updated decision is supported by results from the late-stage HOPE-B trial, in which a single infusion of Hemgenix demonstrated significant increases in mean FIX activity levels of 36.9% at 18 months.
These increases were sustained at 36.7% at 24 months and 38.6% at 36 months and led to an adjusted annualised bleed rate reduction of 64% at 24 and 36 months post-dose compared to the six-month lead-in period.
Additionally, 96% of Hemgenix-treated patients discontinued routine FIX prophylaxis, meaning they no longer required regular infusions for up to 36 months.
In its draft guidance in August last year, NICE’s evaluation committee said that while there was clear evidence that the therapy reduces the number of bleeding episodes haemophilia B patients have each year, there was not enough on how well it works in the long term, meaning cost-effectiveness estimates were “uncertain”.
CSL has now agreed to a managed access programme with NICE under the Innovative Medicines Fund and said it will “work closely and collaboratively with the NHS England selected therapeutic centres to ensure that eligible patients can access treatment as soon as possible”.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.